Diabeteszentrum Duisburg Mitte
- Address
- Heuserstr. 2, 47051 Duisburg, Germany
Diabeteszentrum Duisburg Mitte - Metabolic and Cardiovascular Research Center
Diabeteszentrum Duisburg Mitte is a specialized medical research facility dedicated to advancing the understanding and treatment of metabolic disorders with cardiovascular implications. The center plays a crucial role in evaluating innovative therapeutic approaches for managing dyslipidemia and cardiovascular risk factors in high-risk patient populations.
- Advanced lipid-lowering therapies and cholesterol management strategies
- Novel pharmacological interventions for hypercholesterolemia
- Cardiovascular risk reduction in metabolic disease patients
The center's research portfolio demonstrates expertise in evaluating next-generation lipid-lowering medications, including innovative approaches such as inclisiran for achieving stringent LDL-cholesterol targets in patients requiring intensive cardiovascular risk management. Through rigorous clinical investigation, the facility contributes to establishing evidence-based treatment protocols that optimize quality of life outcomes while ensuring patient safety in complex metabolic and cardiovascular disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diabeteszentrum Duisburg Mitte
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Diamyd (Recombinant Human Glutamate Decarboxylase 2) and Colecalciferol in Preserving Beta Cell Function in HLA DR3-DQ2 Positive Type 1 Diabetes | Diamyd Medical AB | Phase III | Not Recruiting | Mar 2022 | Apr 2026 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azd5004 | 2 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.